Abbott Laboratories (NYSE:ABT) Stock Gets Price Target Reduction from Citigroup

Abbott Laboratories (NYSE:ABT) had its price objective lowered by Citigroup from $125.00 to $122.00 in a report released on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the healthcare product maker’s stock.

Other analysts also recently issued research reports about the stock. Wolfe Research upgraded shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a research report on Thursday, August 13th. UBS Group cut their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Weiss Ratings upgraded Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday, September 18th. BTIG Research cut their price objective on Abbott Laboratories from $134.00 to $125.00 and set a “buy” rating on the stock in a report on Thursday. Finally, JPMorgan Chase & Co. decreased their target price on Abbott Laboratories from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $118.32.

Abbott Laboratories Price Performance

NYSE ABT opened at $103.70 on Thursday. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The company has a market cap of $179.45 billion, a PE ratio of 38.70, a PEG ratio of 1.92 and a beta of 0.59. The stock’s 50-day moving average price is $105.15 and its two-hundred day moving average price is $98.32.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 EPS for the quarter, hitting analysts’ consensus estimates of $1.42. The company had revenue of $13.01 billion during the quarter, compared to the consensus estimate of $12.99 billion. Abbott Laboratories had a net margin of 9.75% and a return on equity of 17.97%. The company’s quarterly revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.30 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.4%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 94.03%.

Institutional Trading of Abbott Laboratories

A number of institutional investors have recently bought and sold shares of the business. IVC Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories in the third quarter worth approximately $241,000. Holos Integrated Wealth LLC boosted its position in Abbott Laboratories by 40.3% in the 3rd quarter. Holos Integrated Wealth LLC now owns 888 shares of the healthcare product maker’s stock worth $92,000 after purchasing an additional 255 shares in the last quarter. Kingswood Wealth Advisors LLC lifted its holdings in Abbott Laboratories by 7.3% in the third quarter. Kingswood Wealth Advisors LLC now owns 12,712 shares of the healthcare product maker’s stock valued at $1,257,000 after acquiring an additional 863 shares during the last quarter. Financial Management Professionals Inc. boosted its holdings in Abbott Laboratories by 2.1% in the third quarter. Financial Management Professionals Inc. now owns 5,878 shares of the healthcare product maker’s stock valued at $581,000 after purchasing an additional 119 shares in the last quarter. Finally, Compass Ion Advisors LLC raised its position in shares of Abbott Laboratories by 7.0% during the 3rd quarter. Compass Ion Advisors LLC now owns 5,106 shares of the healthcare product maker’s stock worth $505,000 after purchasing an additional 332 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Stories Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: New data presented at the European Society for Medical Oncology showed Abbott’s whole-genome sequencing Oncodetect® test delivered a 30% absolute improvement in sensitivity for detecting colorectal-cancer recurrence within two years of surgery. Patients with detectable molecular residual disease also faced a 10.6-fold higher recurrence risk, supporting the test’s clinical value and Abbott’s broader cancer-care strategy. Abbott Oncodetect ESMO data
• Positive Sentiment: Wells Fargo upgraded its stance to “overweight” and raised its price target to $119, while other analysts retained buy or outperform ratings. These targets imply substantial potential upside and suggest Wall Street views the recent pullback as excessive. Wells Fargo rating
• Neutral Sentiment: Abbott’s pacemaker and molecular-diagnostics markets are projected to grow, providing long-term demand opportunities. However, the reports also identify procedure costs, regulatory hurdles, cybersecurity risks and changing disease prevalence as industry constraints. Pacemaker market forecast
• Negative Sentiment: Investors remain concerned about Abbott’s lowered 2026 sales-growth outlook. Management cited diabetes-related pricing pressure and weakness in the electrophysiology portfolio, issues that overshadowed a third-quarter earnings and revenue performance that broadly met expectations. Abbott 2026 guidance
• Negative Sentiment: Abbott plans to spin off its approximately $8.5 billion Nutrition business by 2027. Although the transaction could sharpen the company’s focus and unlock value, investors face near-term uncertainty over separation costs, portfolio mix and the growth profile of the remaining business. Abbott Nutrition spin-off
• Negative Sentiment: A comparative study claimed Catheter Precision’s LockeT device outperformed Abbott’s Perclose vascular-closure system. The potential competitive risk appears limited without evidence of meaningful revenue impact, but it adds pressure to Abbott’s medical-device franchise. LockeT and Perclose study

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women’s health and cardiometabolic care.

The company’s nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.